| NCT ID | NCT07550140 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Reading |
| Condition | Cognition |
| Study Type | INTERVENTIONAL |
| Enrollment | 60 participants |
| Start Date | 2026-05-05 |
| Primary Completion | 2027-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 60 participants in total. It began in 2026-05-05 with a primary completion date of 2027-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study aims to investigate the chronic effects of ETAS® on cognitive, affective and neural outcomes in healthy adults aged 60-80 years with mild to moderate subjective cognitive complaints.
Eligibility Criteria
Inclusion Criteria: * Aging between 60-80 years old * Having normal vision and hearing * Having a body mass index between 18.5 and 30 * Having mild to moderate subjective cognitive complaints Exclusion Criteria: * Smoking * Having food allergies * Following restrictive and/or unbalanced diets (Appendix 6: Are you vegetarian or vegan? Yes / No; Are you currently on a weight-reducing or other special diet? Yes/No If 'Yes', please give details.) * Being diagnosed with any psychiatric or neurologic conditions (e.g. schizophrenia, depression, dementia) including eating disorders * Being diagnosed with any cardiometabolic diseases (including type II diabetes and cardiovascular disease), or hypertension or thrombosis related disorders or suffer from thyroid disease * Currently taking anticoagulants, antiplatelet medication, antidepressants, proton-pump inhibitors * Currently consuming prebiotic or probiotic supplements * Continuous antibiotic use for \> 3 days within 1 month prior to enrolment * Continuous use of weight-loss drug for \> 1 month before screening * Having a significant gastrointestinal (GI) condition affecting absorption including (but not limited to) inflammatory bowel disease; total colectomy or bariatric surgery; irritable bowel disease; end stage renal disease; active cancer, or treatment for any cancer, in last 3 years * History of claustrophobia * Fitted with a pacemaker or artificial heart valve * Have active implants, such as cochlear, ocular, or penile implant * Experience of metal fragments e.g. shrapnel in your eyes or any other part of your body * Drug infusion pump installed * Have any surgically implanted metal in any part of your body, other than dental fillings and crowns (e.g. joint replacement or bone re-construction) * Have had any surgery that might have involved metal implants * Current or historical experience of epilepsy * Have stimulators for nerves, brain or bone installed * Have an intrauterine contraceptive device installed (IUD) * Wear transdermal patches containing metal * Wear a filling, crown, dental post (entirely within the tooth) associated with root canal treatment, retainer, bridge or braces * For scanning, would need to remove coloured contact lenses, nail polish and makeup. * Hearing aid wearer * Body piercings that you cannot or will not remove for the scanning session * Have tattoos or permanent makeup
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07550140 clinical trial?
This trial is open to participants of all sexes, aged 60 Years or older, up to 80 Years, studying Cognition. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07550140 currently recruiting?
Yes, NCT07550140 is actively recruiting participants. Contact the research team at p.hepsomali@reading.ac.uk for enrollment information.
Where is the NCT07550140 trial being conducted?
This trial is being conducted at Reading, United Kingdom.
Who is sponsoring the NCT07550140 clinical trial?
NCT07550140 is sponsored by University of Reading. The trial plans to enroll 60 participants.